RT Journal Article
T1 Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients
A1 Zekri, Khaoula
A1 Barberán, José
A1 Zamorano León, José Javier
A1 Durbán, María
A1 Andrés Castillo, Alcira
A1 Navarro Cuéllar, Carlos
A1 López Farre, Antonio José
A1 López De Andrés, Ana Isabel
A1 Jiménez García, Rodrigo
A1 Martínez Martínez, Carlos Hugo
AB Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality.
PB MDPI
SN 1648-9144
YR 2022
FD 2022-11-15
LK https://hdl.handle.net/20.500.14352/72299
UL https://hdl.handle.net/20.500.14352/72299
LA eng
NO Zekri Nechar, K., Barberán, J., Zamorano León, J. J. et al. «Analysis of Prior Aspirin Treatment on In-Hospital Outcome of Geriatric COVID-19 Infected Patients». Medicina, vol. 58, n.o 11, noviembre de 2022, p. 1649. DOI.org (Crossref), https://doi.org/10.3390/medicina58111649.
DS Docta Complutense
RD 10 abr 2025